These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 14529676)
1. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676 [TBL] [Abstract][Full Text] [Related]
2. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Hann LE; Giess CS; Bach AM; Tao Y; Baum HJ; Barakat RR AJR Am J Roentgenol; 1997 Mar; 168(3):657-61. PubMed ID: 9057510 [TBL] [Abstract][Full Text] [Related]
3. The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. Develioğlu OH; Omak M; Bilgin T; Esmer A; Tüfekçi M Gynecol Oncol; 2004 May; 93(2):328-35. PubMed ID: 15099941 [TBL] [Abstract][Full Text] [Related]
4. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586 [TBL] [Abstract][Full Text] [Related]
5. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Markovitch O; Tepper R; Fishman A; Shapira J; Aviram R; Cohen I Gynecol Oncol; 2004 Dec; 95(3):456-62. PubMed ID: 15581946 [TBL] [Abstract][Full Text] [Related]
6. Value of the progesterone test in screening for endometrial pathology in asymptomatic postmenopausal women receiving treatment with tamoxifen. Lubian López DM; Fernandez YG; Rodríguez BR; López FM; Delgado RC Menopause; 2010; 17(3):487-93. PubMed ID: 20464783 [TBL] [Abstract][Full Text] [Related]
7. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080 [TBL] [Abstract][Full Text] [Related]
8. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen. Marconi D; Exacoustos C; Cangi B; Perroni A; Zupi E; Valli E; Romanini C J Am Assoc Gynecol Laparosc; 1997 May; 4(3):331-9. PubMed ID: 9154782 [TBL] [Abstract][Full Text] [Related]
9. Limited value of sonohysterography for endometrial screening in asymptomatic, postmenopausal patients treated with tamoxifen. Bertelli G; Valenzano M; Costantini S; Rissone R; Angiolini C; Signorini A; Gustavino C Gynecol Oncol; 2000 Sep; 78(3 Pt 1):275-7. PubMed ID: 10985880 [TBL] [Abstract][Full Text] [Related]
10. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Achiron R; Lipitz S; Sivan E; Goldenberg M; Horovitz A; Frenkel Y; Mashiach S Ultrasound Obstet Gynecol; 1995 Aug; 6(2):116-20. PubMed ID: 8535913 [TBL] [Abstract][Full Text] [Related]
11. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study. Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921 [TBL] [Abstract][Full Text] [Related]
12. The value of transvaginal ultrasonography in the endometrial evaluation of breast cancer patients using tamoxifen. Kazerooni T; Ghaffarpasand F; Mosalaei A; Kazerooni Y Med Princ Pract; 2010; 19(3):222-7. PubMed ID: 20357508 [TBL] [Abstract][Full Text] [Related]
13. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen. Lee M; Piao J; Jeon MJ Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174 [TBL] [Abstract][Full Text] [Related]
14. [Tamoxifen and endometrial pathology]. Negoiţă M; Terinte C; Mihailovici MS Rev Med Chir Soc Med Nat Iasi; 2010; 114(4):1114-7. PubMed ID: 21500468 [TBL] [Abstract][Full Text] [Related]
15. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy. Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR; Hum Reprod; 2005 Jan; 20(1):294-301. PubMed ID: 15513977 [TBL] [Abstract][Full Text] [Related]
16. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients. Cohen I; Perel E; Flex D; Tepper R; Altaras MM; Cordoba M; Beyth Y J Clin Pathol; 1999 Apr; 52(4):278-82. PubMed ID: 10474520 [TBL] [Abstract][Full Text] [Related]
17. Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen. Fong K; Kung R; Lytwyn A; Trudeau M; Chapman W; Nugent P; Glanc P; Manchul L; Szabunio D; Myhr T Radiology; 2001 Sep; 220(3):765-73. PubMed ID: 11526280 [TBL] [Abstract][Full Text] [Related]